Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 20, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on March 17, 2006, where Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust, transferred 49,156 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Transaction Date: March 17, 2006.
- Shares Transferred: 49,156 Ordinary Shares.
- Transferor: Abacus (GSK) Trustees Limited (GSK Trust).
- Recipient: Participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Director Interest: Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold interests in the GSK Trust as potential beneficiaries alongside other employees.